Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.
Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...
During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...
Live Science on MSN21h
Severe COVID-19 may shrink cancer tumors, early data suggestImmune cells produced during severe COVID-19 infection may shrink tumors. The unexpected mechanism offers a new therapeutic ...
ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
A new artificial intelligence tool developed by the Hospital Clínic de Barcelona will facilitate the diagnosis of prostate ...
A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...
Researchers have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback